Acellular pertussis vaccines and methods of preparation thereof
US6399076B2 · kind B2 · utility
8Cited by
8References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 9, 1998 |
| Grant date | Jun 4, 2002 |
| Priority date | — |
| Expiry date | Jul 23, 2018 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Acellular pertussis vaccines comprise purified toxin or toxoid thereof, filamentous haemagglutinin, pertactin and fimbrial agglutinogens formulated to confer protection to at least 70% of members of an at-risk population. The fimbrial agglutinogens may be prepared from a Bordetella strain, particularly a B. pertussis strain, by a multiple step procedure involving extraction of the fimbrial agglutinogens from cell paste and concentrating and purifying the extracted material.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.